Terminated PHASE2 INTERVENTIONAL 1-arm NCT01412515

A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

Interventions everolimus

Updated 5 times since 2017 Last updated: Dec 29, 2011 Started: Jun 30, 2008 Primary completion: May 31, 2011 Completion: May 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

results from interim analysis conducted to study interruption

Other terminated trials from Institut National de la Santé Et de la Recherche Médicale, France

See all terminations from Institut National de la Santé Et de la Recherche Médicale, France

A PHASE2 clinical study on Kaposi Sarcoma, this trial is terminated or withdrawn. The trial is conducted by Institut National de la Santé Et de la Recherche Médicale, France and has accumulated 5 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut National de la Santé Et de la Recherche Médicale, France

Data source: Institut National de la Santé Et de la Recherche Médicale, France

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France